ICER Appoints Dr. Pamela Bradt as Chief Scientific Officer

BOSTON, April 2, 2019 – The Institute for Clinical and Economic Review (ICER) has announced the appointment of Pamela Bradt, MD, MPH, as the organization’s Chief Scientific Officer (CSO). Dr. Bradt brings proven experience as a physician leader and researcher across industry and academic settings. As ICER’s new CSO, Dr. Bradt is responsible for leading the organization’s research enterprise, including systematic evidence reviews and health economic modeling. As a member of ICER’s Senior Management Team, Dr. Bradt will also help evolve ICER’s methods of value assessment and expand the application of our work.

“We are thrilled to have Dr. Bradt join ICER’s leadership team as Chief Scientific Officer,” noted Steven D. Pearson, MD, MSc, President of ICER. “Her expertise as a physician and a health economics and outcomes researcher, coupled with her experience as a leader within the pharmaceutical and medical device industries, will help ICER continue to nudge the US health system toward fair pricing, fair patient access, and continued incentives for future innovation.”

Before coming to ICER, Dr. Bradt served as Chief Medical Officer for a biopharmaceutical company focused on rare diseases, and she has extensive experience with both large and midsize global pharmaceutical companies in a variety of disease areas. Prior to joining industry she worked in academic medicine.

Dr. Bradt received a BA in French and psychology from Kansas State University, her MD from the University of Kansas School of Medicine in Kansas City, and her MPH from the University of Texas School of Public Health in Houston. She completed her residency in pediatric medicine at the University of Kansas in Kansas City. Dr. Bradt received the Herbert C. Miller Award for Outstanding Research in Pediatrics, and she was nominated for Physician of the Year in Houston.

“Having worked with health technology assessment organizations around the world, I have long-admired ICER’s commitment to a transparent process and public forum through which all stakeholders can contribute to our understanding of a new treatment’s value,” said Dr. Bradt. “I look forward to joining this impressive team of researchers, following where the evidence leads, and contributing to ICER’s mission of helping all Americans achieve sustainable access to high-value care.”

ICER is continuing to expand its team. For a full listing of open positions, including Senior Scientist and Research Lead, please visit ICER’s website.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.